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ABSTRACT
Introduction: Studies disagree as to whether there is a greater prevalence of hypertension among 
HIV/AIDS patients and the role of antiretroviral therapy. Objective: Evaluate the prevalence of hy-
pertension and risk factors in a cohort of HIV-infected patients, with emphasis on antiretroviral 
therapy. Method: Case-control study conducted at baseline of a cohort, between June/2007 and 
December/2008 in Pernambuco/Brazil. Blood pressure was classifi ed as normal, prehypertension, 
and hypertension. Results: Of 958 patients, 245 (25.6%) had hypertension (cases), 325 (33.9%) had 
prehypertension, and 388 (40.5%) were normotensive (controls). Comparison between hypertensive 
and normotensive patients showed that traditional factors, such as age > 40 (OR = 3.06, CI = 1.91-
4.97), male gender (OR = 1.85, CI = 1.15-3.01), BMI > 25 (OR = 5.51, CI = 3.36-9.17), and triglyc-
erides > 150 mg/dL (OR = 1.69, CI = 1.05-2.71), were independently associated with hypertension. 
Duration of antiretroviral therapy and CD4 > 200 cells/mm3 were associated with hypertension in 
univariate analysis, but did not remain in fi nal model. Type of antiretroviral schema and lipodystro-
phy showed no association with hypertension. Conclusion: Hypertension in HIV/AIDS patients is 
partially linked to  invariable  factors, such as age and sex. Efforts should be directed toward control-
ling reversible factors, particularly excessive weight gain and unsuitable diet.
Keywords: HIV/AIDS, hypertension, antiretroviral therapy, cardiovascular risk.
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INTRODUCTION
Potent antiretroviral therapy (HAART) has 
resulted in lasting suppression of HIV repli-
cation, reduction of opportunistic infections 
and malignancies associated with AIDS, and 
has had a substantial impact on the survival 
rate and quality of life of infected individu-
als.1 However, the potential to keep these pa-
tients under treatment for decades may be 
limited by a variety of metabolic and cardio-
vascular abnormalities observed in patients 
on HAART, including dyslipidemia, fat redis-
tribution, insulin resistance,2 hypertension,3 
and coronary ischemia.4 
Two large prospective studies4,5 showed 
that the HIV infected population is at in-
creased risk of cardiovascular disease in the 
long term. However, individual cardiovas-
cular risk is determined by a complex over-
lapping of several risk factors that include 
age, family history, smoking, hypertension, 
diabetes, and high blood lipids.6 In the pe-
riod prior to HAART, high blood pressure 
in infected patients was often associated 
with complications related to HIV, such as 
renal failure and vasculopathy.7 In post-
HAART period, some studies have raised 
the possibility that HAART may also induce 
hypertension8-15 through the acceleration of 
atherogenesis and subsequent hardening of 
the vessel wall.16 
Studies on blood pressure in HIV in-
fected patients show conflicting results 
regarding the increased prevalence of dis-
ease among patients on HAART and the 
role of different treatment regimens in its 
genesis.3,13,17,18 Given the importance of the 
subject and the urgency in adopting pre-
ventive measures for cardiovascular damage 
among patients with HIV/AIDS on antiret-
roviral treatment, this study was conducted 
to assess the prevalence of hypertension and 
possible risk factors in a cohort of 1,000 
HIV patients, paying particular attention 
to the role of antiretrovirals in the develop-
ment of the disease.
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METHODS 
A case-control study was conducted at baseline assess-
ment of a cohort of outpatients with HIV/AIDS treated 
at the Infectious Diseases Unit, Oswaldo Cruz Medical 
College, University of Pernambuco and Correia Picanço 
Hospital of the Pernambuco State Department of Health, 
Brazil, from June 2007 to December 2008, and evaluated 
consecutively. After receiving the information, patients 
signed the informed consent form, answered a question-
naire and were submitted to measurement of anthropo-
metric data, blood pressure and collection of blood sam-
ples to assess fasting blood glucose and lipids. Data on 
HIV infection and antiretroviral therapy were obtained 
from medical records. The study was approved by the 
Ethics Committee (protocol number 052/05). All partici-
pants were aged 18 years or over. Pregnant women and 
patients with signs of active AIDS or hospitalization in 
the previous three months were excluded. 
Diagnosis of hypertension was confirmed on a sec-
ond visit, not more than two months later, when two BP 
measurements were taken in an upper limb, and mean 
systolic and diastolic pressures were calculated. Patients 
were classified according to the criteria of the Joint Na-
tional Committee on Prevention, Detection, Evaluation, 
and Treatment of High Blood Pressure (JNC 7),19 which 
considers the following classifications of blood pressure: 
normal (systolic BP < 120 mmHg and diastolic BP < 80 
mmHg); prehypertension (systolic BP between 120-139 
mmHg or diastolic BP between 80-89 mmHg); and hy-
pertension (systolic BP > 140 mmHg and diastolic BP > 
90 mmHg). 
Cases were defined as patients with systolic BP > 140 
mmHg and diastolic BP > 90 mmHg, measured on at 
least two occasions, or a previous diagnosis of hyperten-
sion and blood pressure levels controlled with an anti-
hypertensive drug. Patients with normal blood pressure 
(systolic BP < 120 mmHg and diastolic BP < 80 mmHg) 
were considered controls.
DATA ANALYSIS 
All univariate and multivariate analyses were carried out 
using the R statistical program (R Project for Statistical 
Computing www.r-project.org). 
To test the assumption of normality for continuous 
variables involved in the study, the Shapiro Wilk test was 
used. In the comparative analysis of quantitative vari-
ables we used Student t-test. Chi-square and, when nec-
essary, Fisher’s test was used to test the association be-
tween dependent variable and potential risk factors. All 
conclusions were drawn at a 5% level of significance. 
All the variables that, in the univariate analysis, 
showed a p-value < 0.25 for association with the depend-
ent variable were introduced in a multivariate model 
(multiple logistic regression), by block, and those that 
remained in the model had a p-value of < 0.05. Then 
there was a final multivariate analysis that included the 
variables selected in each block, using as a cutoff point 
a p-value < 0.05.
RESULTS 
Of the 1,000 HIV-positive patients eligible for the study, 
958 agreed to participate and attended two or more vis-
its. Hypertension was detected in 245 patients (25.6%), 
36 (14.8%) of which were controlled with an antihyper-
tensive drug. A total of 325 (33.9%) had pre-hyperten-
sion and 388 (40.5%) were normotensive (controls). In 
the univariate analysis, the mean age of hypertensive 
patients (Figure 1) was significantly higher than that of 
prehypertensive and hypertensive ones (43.4 + 9.2 years 
X 40.4 + 9.8 years X 36.9 + 8.9 years (p < 0.0001). The 
average duration of antiretroviral drugs use (Figure 2) 
was higher in hypertensive patients than in controls 
(1,742.6 + 1,211.5 X 1,389.2 + 1,182.6 days) (p = 0.0088), 
and waist circumference was also higher in hyperten-
sive patients than in prehypertensive and normotensive 
ones (80.7 + 8.7 cm X 86.6 + 10.1 cm X 90.2 + 10.5 cm) 
(p < 0.0001). 
In the univariate analysis of biological factors, age, 
male gender, and a family history of hypertension were 
associated with hypertension (Table 1); and among 
living habits, the consumption of vegetables and level 
of physical activity were associated with the presence 
of disease (Table 2). Of the metabolic characteristics, 
BMI > 25, high waist circumference (NCEP criteria)20, 
level of cholesterol > 200 mg/dL, blood glucose levels 
> 100 mg/dL, and triglyceride values of > 150 mg/dL 
were associated with hypertension. In contrast, lipodys-
trophy was not associated with the disease (Table 3). 
On assessing the factors associated with infection 
and antiretroviral treatment, we observed that CD4-
lymphocyte count < 200 cells/mm3, time elapsed since 
the diagnosis of HIV infection > 5 years, time elapsed 
since the diagnosis of AIDS, and duration of antiretrovi-
ral treatment > 1 year were all associated with the pres-
ence of hypertension. In this same analysis, the use of 
antiretroviral regimens containing protease inhibitors 
was not associated with hypertension (Table 4). 
Figure 3 presents the results of multivariate logistic 
regression and show that age > 40 years (OR = 3.06, CI 
= 1.91-4.97), male gender (OR = 1.85, CI = 1.15-3.01), 
body mass index > 25 (OR = 5.51, CI = 3.36-9.17), and 
triglycerides > 150 mg/dL (OR = 1.69, CI = 1.05-2.71) 
were independently and significantly associated with 
hypertension.
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Table 1. Comparison of biological characteristics of 245 hypertensive patients (cases) and 388 normotensives 
(controls) in a cohort of individuals living with HIV/AIDS in Pernambuco, Brazil
Biological factors             Hypertensive                Normotensive 
OR 
               95% CI  
p-value
  n % n %  lower upper  
Age
 < 40 89/245 36.33 241/388 62.11 1.00 - - -
 40 + 156/245 63.67 147/388 37.89 2.87 2.06 4.01 < 0.0001
Sex 
 Female 89/245 36.33 175/388 45.10 1.00 - - -
 Male 156/245 63.67 213/388 54.90 1.44 1.04 2.00 0.0292
Ethnicity                
 White 63/245 25.71 106/388 27.32 1.00 - - -
 Black 28/245 11.43 43/388 11.08 1.1 0.62 1.94 0.7531
 Yellow 4/245 1.63 5/388 1.29 1.35 0.31 5.49 0.7305
 Brown 145/245 59.18 227/388 58.51 1.07 0.74 1.57 0.7063
 Indigenous 5/245 2.04 7/388 1.8 1.21 0.34 4.05 0.7656
Family history of hypertension               
 No 174/245 71.02 231/388 60.31 1.00 - - - 
 Yes 52/245 21.22 116/388 30.29 1.68 1.15 2.47 0.0077
 Not known 19/245 7.76 36/388 9.4 1.18 0.61 2.23 0.6197
χ2, chi-square; OR, odds ratio.
Figure 1: Mean and standard deviation of age of patients with 
HIV/AIDS with hypertension (cases), prehypertension and 
normotensive (controls).
Figure 2: Mean and standard deviation of duration of therapy 
(in days) in patients with HIV/AIDS with hypertension (cases), 
prehypertension and normotensive (controls).
Figure 3: Model of the final multivariate analysis of association between hypertension and biological characteristics, living 
habits, metabolic and anthropometric factors related to HIV infection and antiretroviral therapy.
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Table 2. Comparison of lifestyle of 245 hypertensive and 388 normotensive patients in a cohort of indi-
viduals with HIV/AIDS in Pernambuco, Brazil
Lifestyle                 Hypertensive            Normotensive 
OR 
               95% CI  
p-value
  n % n %  lower upper  
Smoking history               
 Never smoked 109/242 45.04 167/384 43.49 1.00 - - - 
 Former smoker 77/242 31.82 111/384 28.91 1.06 0.73 1.55 0.7520
 Current smoker 56/242 23.14 106/384 27.6 0.81 0.54 1.21 0.3048
Cocaine               
 Never used 227/244 93.03 348/388 89.69 1.00 - - -
 Already used 17/244 6.97 40/388 10.31 0.65 0.86 2.83 0.1533
Consumption of alcohol               
 Teetotaler / Light drinker 201/228 88.16 304/348 87.36 1.00 - - -
 Heavy / Dependent drinker  27/228 11.84 44/348 12.64 0.93 0.55 1.54 0.7747
Consumption of vegetables               
 Yes 171/240 71.25 242/383 63.19 1.00 - - - 
 No 69/240 28.75 141/383 36.81 0.69 0.49 0.98 0.0387
Consumption of fruits               
 Yes 139 57.68 193 50.79 1.00 - - -
 No 102/241 42.32 187/380 49.21 0.77 0.56 1.06 0.1150
Physical activity               
 High  60/245 24.49 105/388 27.06 1.00 - - -
 Moderate  56/245 18.37 58/388 7.99 1.89 1.14 3.14 0.0133
 Low 141/245 53.88 236/388 56.96 1.17 0.78 1.76 0.4478
χ2, chi-square; OR, Odds Ratio.
Table 3. Comparison of anthropometric and metabolic characteristics of 245 hypertensive and 388 normoten-
sive patients in a cohort of individuals with HIV/AIDS in Pernambuco, Brazil
Metabolic factors                  Hypertensive             Normotensive 
OR
              95% CI 
p-value
  n % n %  lower upper
BMI                
 < 25 116/245 47.35 312/382 81.68 1.00 -  -  - 
 25 + 129/245 52.65 70/382 18.32 4.95 3.47 7.14 < 0.0001
Abdominal circumference (NCEP) 
 Normal 172/244 70.49 350/387 90.44 1.00 - - -
 Altered * 72/244 29.51 37/387 9.56 3.96 2.57 6.18 < 0.0001
Total cholesterol (mg/dL)               
 ≤ 200 96/139 69.06 208/258 80.62 1.00 - - -
 > 200 43/139 30.94 50/258 19.38 1.86 1.15 2.99 0.0101
HDL-cholesterol (mg/dL)             
 > 40 69/144 47.92 117/255 45.88 1.00 - - -
 ≤ 40 75/144 52.08 138/255 54.12 0.92 0.61 1.39 0.6956
LDL-cholesterol (mg/dL)                
 < 130 85/109 77.98 167/196 85.2 1.00 - - -
 130 + 24/109 22.02 29/196 14.8 1.62 0.88 2.97 0.1130
Triglycerides (mg/dL)               
 < 150 58/142 40.85 168/265 63.4 1.00 - - -
 150 + 84/142 59.15 97/265 36.6 2.51 1.65 3.82 < 0.0001
Glycemia (mg/dL)                
 < 100 111/140 79.29 236/253 93.28 1.00 - - -
 100 + 29/140 20.71 17/253 6.27 3.62 1.93 7.00 < 0.0001
Lipodystrophy               
 No 111/206 53.88 139/291 47.77 1.00 - - -
 Yes 95/206 46.12 152/291 52.23 0.78 0.54 1.11 0.1794
χ2, chi-square; OR, odds ratio. 
 * Altered = Women > 88 cm; Men > 102 cm.
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DISCUSSION 
Although blood pressure levels are usually considered in studies 
of cardiovascular disease risk in populations of HIV-infected 
patients, the prevalence of hypertension, the focus of this study, 
has received little attention, and data are controversial and vary 
widely.3,13,14,21 Possible explanations for these discrepant results 
include differences in study design, methodological aspects, the 
cut values for hypertension and differences in the populations 
studied. Using the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure 
(JNC 7) criteria,19 25.6% of 958 patients with HIV/AIDS are 
hypertensive, a proportion similar to that found in the region, 
and in Brazil as a whole, in uninfected individuals.22,23 
The comparison between HIV/AIDS non-hypertensive 
and hypertensive patients showed that traditional risk fac-
tors were associated with the presence of hypertension, such as 
older age, male gender, overweight/obesity, family history of 
hypertension, and increased levels of triglycerides. Lipod-
ystrophy was not associated with the presence of hyperten-
sion. The duration of HAART exposure was associated with 
hypertension and the levels of CD4 lymphocytes below 200 
cells/mm3 showed a tendency to be protective against hyper-
tension in univariate analysis; nevertheless, none of them re-
mained in the fi nal model. The type of antiretroviral schema 
was not associated with the onset of hypertension. 
The fi ndings of this study reinforce the hypothesis that 
HIV/AIDS and/or antiretroviral therapy, despite signifi -
cantly increase the risk of atherosclerosis and cardiovascular 
disease,4,17 do not appear to have a signifi cant impact on the 
prevalence and genesis of hypertension compared with the 
factors traditionally associated with the disease, which is in 
agreement with the fi ndings of Baekken et al.,3 Bergensen et 
al.,13 and Khalsa et al.21
Table 4. Comparison of factors related to HIV infection and antiretroviral therapy in 245 hypertensive and 388 
normotensive patients in a cohort of individuals with HIV/AIDS in Pernambuco, Brazil
Factors related                  Hypertensive            Normotensive 
OR 
               95% CI  
p-value
to HIV infection
 n % n %  lower upper  
Use of HAART              
 No 38/217 17.51 71/343 20.7 1.00 - - -
 Yes 179/217 82.49 272/343 79.3 1.23 0.80 1.92 0.3537
Current HAART status            
 Without HAART 30/214 13.62 61/327 18.65 1.00 - - -
 With PI 89/214 41.78 141/327 43.12 1.28 0.77 2.16 0.3388
 Without PI 95/214 44.60 125/327 38.23 1.55 0.93 2.60 0.0957
Duration of HAART exposure                
 Up to 1 year 21/169 12.43 68/254 26.77 1.00 - - -
 1 to 5 years 80/169 47.34 102/254 40.16 2.53 1.46 4.51 0.0014
 5 + years 68/169 40.23 84/254 33.07 2.62 1.49 4.72 0.0013
Time of diagnosis of HIV               
 Up to 1 year 19/153 12.42 49/253 19.37 1.00 - - -
 1 to 5 years 61/153 39.87 113/253 44.66 1.39 0.76 2.62 0.2912
 5 + years 73/153 47.71 91/253 35.97 2.07 1.14 3.89 0.0200
CD4 Nadir                 
 200 + 119/188 66.30 168/290 57.93 1.00 - - -
 100 – 200 33/188 17.55 56/290 19.31 0.83 0.59 1.15 0.2750
 < 100 36/188 19.15 66/290 22.76 1.04 0.70 1.56 0.8310
Current CD4 lymphocyte count               
 500 + 49/126 38.89 63/200 31.50 1.00 - - -
 200 – 500 61/126 48.41 98/200 49.00 0.80 0.49 1.31 0.3743
 < 200 16/126 12.70 39/200 19.50 0.53 0.26 1.04 0.0698
Current viral load                
 < 10,000 54/67 80.60 92/119 77.31 1.00 - - -
 10,000 – 100,000 8/67 11.94 22/119 18.49 0.62 0.24 1.44 0.2841
 100,000 + 5/67 7.46 5/119 4.20 1.42 0.39 4.93 0.5776
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There are, however, a number of aspects that deserve 
special mention: while the presence of lipodystrophy, hy-
percholesterolemia, and low levels of HDL fraction of cho-
lesterol were not associated with hypertension, the increase 
in triglycerides was associated with the disease. Consider-
ing that the serum triglycerides are the lipids that most fre-
quently undergo change with the use of anti-retrovirals,24 
the question arises as to whether this increase does not re-
ﬂ ect the association of hypertension with the use of HAART 
for long periods or the use of some specifi cally antiretroviral 
schema, especially a schema containing Protease Inhibitors 
(PI), as suggested by Baekken et al.,3 Crane et al.18 The rise in 
triglyceride levels related to antiretroviral treatment is high-
er for the fi rst generation of non-nucleoside reverse tran-
scriptase inhibitors (efavirenz and nevirapine) than for the 
protease inhibitors (PI), although the rise in LDL cholesterol 
is similar in both groups.24 Moreover, the drugs of the group 
of nucleoside reverse transcriptase inhibitors, such as stavu-
dine and zidovudine, may also play a role in these changes.24 
As for the PI, the highest rises in triglycerides are associ-
ated with booster regimens containing ritonavir.24 Bearing 
in mind that preferred antiretroviral regimens suggested 
by the National STD/AIDS Program in Brazil is composed 
of zidovudine and lamivudine associated with efavirenz or 
one boosted PI (lopinavir or atazanavir both boosted with 
ritonavir),25 the increase in triglycerides could signal the use 
of HAART in its different treatment regimens, without any 
preferential schema. On the other hand, as mentioned above, 
the duration of antiretroviral therapy was associated with 
hypertension in the univariate analysis, but this factor was 
no longer present in the multivariate analysis. Furthermore, 
the combination of an increase in triglycerides and hyper-
tension could merely reﬂ ect a dietary disorder, or a diet rich 
in carbohydrates, so common among the obese. 
As for obesity, this was a risk factor strongly associated 
with hypertension in this study, as in all studies that deal 
with hypertension in the general population.19,22 Obesity of 
individuals with HIV/AIDS may be associated with exces-
sive weight gain during treatment with HAART and should 
be avoided. However, while uninfected individuals often 
have the desire and strive to lose weight, among the infected 
patients, particularly those who already had symptoms of 
AIDS, the loss of weight enhances the fantasy of appearing 
ill and this is a “taboo” among the infected. Thus, it is not 
only lipodystrophy that merits attention. A recent Brazilian 
study showed that the majority of adults living with HIV/
AIDS have a diet that needs improvement, and obesity was 
associated with a poorer quality of diet.26 Nutritional inter-
ventions aimed at maintaining a healthy weight should be 
emphasized in the care of HIV patients25 and may offer pro-
tection against the onset of hypertension in this group.
Moreover, in subjects with CD4 < 200, the risk of hyper-
tension was lower. Certainly, loss of weight, and lower levels 
of triglycerides, most frequently found in patients with CD4 
lymphocyte counts of less than 200 cells/mm3,24,27 could be 
reﬂ ected in the lower prevalence of hypertension in this 
group. 
This study has the limitations inherent in a case control 
study, i.e., it does not determine the origin but the combina-
tion of factors, and data reﬂ ect a specifi c population (young 
and predominantly male). However, it has the advantage of 
being a study in which patients were prospectively selected 
based on the criteria of JNC 7 and of having excluded pre-
hypertensive patients from the analysis, thereby highlighting 
the differences between the groups. 
Finally, hypertension in patients with HIV/AIDS is as-
sociated with factors such as age > 40 years, BMI > 25, high 
triglyceride level, and male gender. Therefore, the control of 
the reversible factors associated with hypertension, particu-
larly the reinforcement of dietary advice guidance and pre-
vention of excessive weight gain, may represent an impor-
tant advance in the prevention of cardiovascular morbidity 
among people living with HIV/AIDS.
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